Publications

Posters & Presentations

ABI-5366

July 2025
49th Annual International Herpesvirus Workshop (IHW)
ABI-5366 and ABI-1179, Two Potent, Long-Acting Helicase Primase Inhibitors for the Treatment of Recurrent Genital Herpes Oral presentationPoster
Contreras, et al.
July 2025
Poster
STI & HIV 2025 World Congress
Estimating Genital Herpes Prevalence and Treatment Patterns Among US Healthcare–Engaged Individuals: Insights From Claims Data
Liu, et al.
July 2025
Poster
STI & HIV 2025 World Congress
ABI-5366, a Potent HSV Helicase-Primase Inhibitor, with Potential for Weekly or Monthly Oral Dosing for Recurrent Genital Herpes
Shen, et al.
July 2025
Poster
STI & HIV 2025 World Congress
ABI-5366, a Novel, Oral, Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor: Interim Safety and Pharmacokinetic Results From a Phase 1a Study in Healthy Participants
Gane, et al.
April 2025
Poster
European Society of Clinical Microbiology and Infection Diseases (ESCMID)
Preclinical Profile of ABI-5366, a Novel Potent HSV Helicase-Primase Inhibitor, With Potential for Weekly or Monthly Oral Dosing for the Treatment of Recurrent Genital Herpes
Shen, et al.
April 2025
Poster
European Society of Clinical Microbiology and Infection Diseases (ESCMID)
The Safety and Pharmacokinetics of ABI-5366, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor: Interim Results from a Phase 1a/1b Study in Healthy Participants
Gane, et al.
April 2025
Poster
European Society of Clinical Microbiology and Infection Diseases (ESCMID)
Estimating Genital Herpes Prevalence and Treatment Patterns Among US Healthcare-Engaged Individuals: Insights from Claims Data
Liu, et. al.
March 2025
Poster
38th Annual Conference on Antiviral Research (ICAR)
The Helicase-Primase Inhibitor ABI-5366 is a Novel, Potent, Long-Acting Inhibitor for the Treatment of Recurrent Genital Herpes
Contreras, et al.
July 2024
Poster
48th Annual International Herpesvirus Workshop (IHW)
The Helicase-Primase Inhibitor ABI-5366 Is a Novel, Potent, Long-Acting Inhibitor for the Treatment of Recurrent Genital Herpes
Contreras, et al.
July 2023
47th Annual International Herpesvirus Workshop (IHW)
Pre-Clinical Characterization of ABI-5366: A Highly Potent Long-Acting Helicase-Primase Inhibitor for the Treatment of High Recurrence Genital Herpes Oral presentationPoster
Contreras, et al.

ABI-1179

July 2025
49th Annual International Herpesvirus Workshop (IHW)
ABI-5366 and ABI-1179, Two Potent, Long-Acting Helicase Primase Inhibitors for the Treatment of Recurrent Genital Herpes Oral presentationPoster
Contreras, et al.
July 2025
Poster
STI & HIV 2025 World Congress
Estimating Genital Herpes Prevalence and Treatment Patterns Among US Healthcare–Engaged Individuals: Insights From Claims Data
Liu, et al.
July 2025
Poster
STI & HIV 2025 World Congress
ABI-1179, a Novel, Orally Administered, Long-Acting HSV Helicase-Primase Inhibitor: Interim Analysis of Safety and Pharmacokinetic Data From a Phase 1a Study in Healthy Participants
Gane, et al.
April 2025
Poster
European Society of Clinical Microbiology and Infection Diseases (ESCMID)
Estimating Genital Herpes Prevalence and Treatment Patterns Among US Healthcare-Engaged Individuals: Insights from Claims Data
Liu, et. al.
March 2025
Poster
38th International Conference on Antiviral Research (ICAR)
Preclinical Characterization of ABI-1179, a Potent Helicase Primase Inhibitor for the Treatment of Recurrent Genital Herpes
Cho, et al.
July 2024
48th Annual International Herpesvirus Workshop (IHW)
Preclinical Characterization of ABI-1179, a Potent Helicase Primase Inhibitor for the Treatment of Recurrent Genital Herpes Oral presentationPoster
Cho, et al.

ABI-4334

May 2025
Poster
THE EASL CONGRESS (EASL)
Sustained Inhibition of HBV Replication and HBsAg Levels After Long-Term Treatment with CAM ABI-4334 in Human Hepatocytes
Michelet, et al.
September 2023
Oral Presentation
International HBV Meeting
ABI-4334, a Novel Inhibitor of Hepatitis B Virus Core Protein, Disrupts DL-DNA Containing Capsids and Prevents HBV DNA Integration
Li, et al.
June 2023
Oral Presentation
Science of HBV Cure
Development of a Highly Potent Next-Generation Core Inhibitor for the Treatment of Chronic Hepatitis B Infection
Dr. Kathryn M. Kitrinos
June 2023
Poster
The EASL Congress (EASL)
The Safety and Pharmacokinetics of ABI-4334, a Novel Next-Generation HBV Core Inhibitor: Interim Results From a Phase 1 Study in Healthy Volunteers
Gane, et al.
June 2023
Poster
The EASL Congress (EASL)
Next Generation Core Inhibitors ABI-H3733 and ABI-4334 have Significantly Improved Potency and Target Coverage for Both Antiviral and cccDNA Formation Activities Compared to First-Generation Core Inhibitors
Unchwaniwala, et al.
November 2022
Poster
The Liver Meeting (AASLD)
ABI-4334, a Novel Hepatitis B Core Inhibitor, Accelerates Capsid Assembly and Inhibits cccDNA Formation via Multiple Pathways
Unchwaniwala, et al.
September 2022
Poster
International HBV Meeting
Next-Generation Core Inhibitors Demonstrate Increased Potency and Distinct Biochemical Properties Compared to First-Generation Core Inhibitors
Unchwaniwala, et al.
June 2022
Poster
The EASL Congress (EASL)
ABI-4334, a Novel Inhibitor of Hepatitis B Virus Core Protein, Promotes Formation of Empty Capsids and Prevents cccDNA Formation by Disruption of Incoming Capsids
Unchwaniwala, et al.
November 2021
Poster
The Liver Meeting (AASLD)
Preclinical Characterization of ABI-4334, a Novel, Highly Potent Core Inhibitor for the Treatment of Chronic Hepatitis B virus Infection
Xu, et al.

ABI-6250

May 2025
Poster
THE EASL CONGRESS (EASL)
Preclinical Profiling of ABI-6250, a First-In-Class Oral Therapeutic Candidate for Chronic Hepatitis D
Windisch, et al.
March 2025
38th International Conference on Antiviral Research (ICAR)
Preclinical Profiling of ABI-6250, a Novel Small-Molecule Orally Bioavailable Drug Candidate for the Treatment of Chronic Hepatitis D Virus Infections PosterOral Presentation
Unchwaniwala, et al.
September 2024
Poster
International HBV Meeting
Preclinical Profiling of ABI-6250, a Novel, Orally Bioavailable, Small-Molecule Therapeutic Drug Candidate for the Treatment of Chronic Hepatitis DVirus Infection
Unchwaniwala, et al.
July 2024
Oral Presentation
SHC
Preclinical Profiling of ABI-6250, a Novel Orally Bioavailable Small-Molecule Therapeutic Candidate for the Treatment of Chronic Hepatitis D
Dr. Marc P. Windisch
June 2024
Poster
The EASL Congress (EASL)
Preclinical Profiling of ABI-6250, a Novel Orally Bioavailable Small-Molecule Therapeutic Candidate for the Treatment of Chronic Hepatitis D
Windisch, et al.